Incheon, South Korea

Minseob Lee

USPTO Granted Patents = 1 

Average Co-Inventor Count = 16.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Minseob Lee: Innovator in Antibody-Drug Conjugates

Introduction

Minseob Lee is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates. His innovative work aims to enhance the efficacy of cancer treatments.

Latest Patents

Minseob Lee holds a patent for an "Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same." This invention relates to a conjugate where an antibody is linked to a cytotoxic drug through an enzyme-cleavable peptide linker. This linker is capable of directly binding to a lysine residue of the antibody, which is crucial for the targeted delivery of the drug.

Career Highlights

Minseob Lee is currently employed at Celltrion Inc., a leading biopharmaceutical company known for its innovative therapies. His work at Celltrion has positioned him as a key player in the development of advanced cancer treatments. He has successfully contributed to the company's mission of providing effective and safe therapeutic options.

Collaborations

Minseob Lee collaborates with talented colleagues, including Young Jun Park and Jin-kyo Jeong. Their combined expertise fosters a dynamic research environment that drives innovation in the field of antibody-drug conjugates.

Conclusion

Minseob Lee's contributions to the field of biopharmaceuticals, particularly through his patent on antibody-drug conjugates, highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…